| Literature DB >> 34707689 |
Asaf Levartovsky1, Yiftach Barash2, Shomron Ben-Horin1, Bella Ungar1, Shelly Soffer3, Marianne M Amitai2, Eyal Klang2, Uri Kopylov1.
Abstract
BACKGROUND: Intra-abdominal abscess (IA) is an important clinical complication of Crohn's disease (CD). A high index of clinical suspicion is needed as imaging is not routinely used during hospital admission. This study aimed to identify clinical predictors of an IA among hospitalized patients with CD using machine learning.Entities:
Keywords: Crohn complications; abscess; machine learning
Year: 2021 PMID: 34707689 PMCID: PMC8543712 DOI: 10.1177/17562848211053114
Source DB: PubMed Journal: Therap Adv Gastroenterol ISSN: 1756-283X Impact factor: 4.409
Figure 1.Flow chart showing the screened, included, and excluded patients.
CD, Crohn’s disease; ED, emergency department.
Characteristics of total study population.
| Study population, | |
| Male gender, | 167 (54) |
| Age, | 37 (26–50) |
| No prior hospitalization, | 214 (69.3) |
| Comorbidities, | |
| Hypertension | 18 (5.8) |
| Dyslipidemia | 13 (4.2) |
| Hypothyroidism | 6 (1.9) |
| COPD | 3 (0.97) |
| Diabetes mellitus | 5 (1.6) |
| CD extent at diagnosis, | |
| L1 (ileal) | 127 (56.2) |
| L2 (colonic) | 17 (7.5) |
| L3 (ileo-colonic) | 82 (36.3) |
| Perianal disease | 94 (41.6) |
| CD behavior at diagnosis, | |
| B1 (nonstricturing and nonpenetrating) | 110 (38.9) |
| B2 (stricturing) | 57 (20.1) |
| B3 (penetrating) | 116 (41) |
| Current IBD treatment, | |
| Immunomodulators | 47 (15.2) |
| Biologics | 48 (15.5) |
| ASA | 34 (11) |
| Steroids | 35 (11.3) |
| Past biologic treatment, | |
| Infliximab | 113 (36.6) |
| Adalimumab | 122 (39.5) |
| Vedolizumab | 53 (17.1) |
| Ustekinumab | 45 (14.6) |
| Current or past smoker, | 88 (28.5) |
| EIM, | 84 (27.9) |
ASA, 5-aminosalicylic acid; CD, Crohn’s disease; COPD, chronic obstructive pulmonary disease; EIM, extra-intestinal manifestation; IBD, inflammatory bowel disease; IQR, interquartile range.
IBD and abscess characteristics of patients with an IA on presentation.
| Number of patients | 40 |
| Male, | 21 (52.5) |
| Female, | 19 (47.5) |
| CT, | 39 (97.5) |
| MRE, | 1 (2.5) |
| Age at CD diagnosis, years, median (IQR) | 22.5 (17.25–29) |
| Current or past smoker, | 4 (10) |
| Previous abdominal surgery, | 7 (17.5) |
| EIM, | 5 (12.5) |
| Abscess size, mm, median (IQR) | 32 (20.5, 44.5) |
| Small (⩽30 mm) | 20 (50) |
| Large (>30 mm) | 20 (50) |
| Number of abscess, | |
| 1 | 28 (70) |
| 2 | 5 (12.5) |
| 3 or more | 7 (17.5) |
| CD extent at diagnosis, | |
| L1 (ileal) | 20 (50) |
| L2 (colonic) | 4 (10) |
| L3 (ileo-colonic) | 16 (40) |
| Perianal disease | 3 (7.5) |
| CD behavior at diagnosis, | |
| B1 (nonstricturing and nonpenetrating) | 29 (72.5) |
| B2 (stricturing) | 7 (17.5) |
| B3 (penetrating) | 4 (10) |
| B2 + B3 | 2 (4.8) |
| Previous therapy, | |
| Immunomodulators | 14 (35) |
| Biologics | 15 (37.5) |
| ASA | 18 (45) |
| Previous biologic therapy, | |
| Infliximab | 18 (45) |
| Adalimumab | 15 (33.3) |
| Vedolizumab | 6 (15) |
| Ustekinumab | 6 (15) |
ASA, 5-aminosalicylic acid; CD, Crohn’s disease; CT, computed tomography; EIM, extra-intestinal manifestation; IA, intra-abdominal abscess; IBD, inflammatory bowel disease; IQR, interquartile range; MRE, magnetic resonance enterography.
Characteristics of patients with an IA and control.
| Variable | Non-abscess population
( | IA population ( | |
|---|---|---|---|
| Male gender | 54.3% | 52.5% | 0.83 |
| Age (IQR) | 38 (28–51) | 30 (23–42.5) |
|
| Days hospitalized (IQR) | 4 (3–7) | 6.5 (4–11) |
|
| Clinical features | |||
| Pulse (IQR) | 91 (77.25–103) | 99.5 (88.25–114.75) |
|
| Fever | 36.9 ± 2.2 | 37 ± 0.86 | 0.23 |
| Systolic blood pressure (IQR) | 117 (108–127) | 111.5 (105–122) | 0.07 |
| Laboratory values (IQR) | |||
| WBC | 10.76 (8.13–14.31) | 13.67 (10.7–16.64) |
|
| NLR | 5.9 (3.67–11.12) | 9.2 (4.87–17.14) |
|
| Hemoglobin | 12.96 (11.65–14.24) | 11.86 (10.4–12.43) |
|
| Platelets | 299 (231.5–377.5) | 364 (303–486. 5) |
|
| Creatinine | 0.79 (0.68–0.97) | 0.8 (0.64–1.01) | 0.9 |
| LDH | 193 (154.75–250) | 162 (128–227.5) |
|
| Sodium | 137 (135–138.75) | 136 (134–138) | 0.06 |
| Urea | 24.5 (19–31.75) | 23.5 (19.25–28) | 0.33 |
| CRP | 38.2 (11.96–92.8) | 114.21 (85–150.2) |
|
CRP, C-reactive protein; IA, intra-abdominal abscess; IQR, interquartile range; LDH, lactate dehydrogenase; NLR, neutrophil-to-lymphocyte ratio; WBC, white blood cells.
The p value <0.05 was considered statistically significant (highlighted in bold).
Figure 2.Nomogram demonstrating the PPV of an IA in patients with CD, based on CRP cutoff values (above 5, 25, 45, 65, 85, or 105 mg/l). The PPV of an IA was greater as CRP cutoff values were higher. The CRP above 5 mg/l had a PPV of 14.6%, whereas 29.4% for a CRP cutoff above 85 mg/l.
CD, Crohn’s disease; CRP, C-reactive protein; IA, intra-abdominal abscess; PPV, positive predictive value.
Figure 3.AUC graphs of RFE experiments of the (a) logistic regression and (b) random forest models.
AUC, area under the receiver operating characteristic curve; RFE, recursive feature elimination.